Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study

BACKGROUND: This retrospective, multicenter study evaluated the effect of pemafibrate treatment on liver function and fibrosis by liver function tests (LFTs) and various fibrotic biomarkers including FibroScan in non-alcoholic fatty liver disease (NAFLD) with hypertriglyceridemia. METHODS: A total o...

Descripción completa

Detalles Bibliográficos
Autores principales: Morishita, Asahiro, Oura, Kyoko, Takuma, Kei, Nakahara, Mai, Tadokoro, Tomoko, Fujita, Koji, Tani, Joji, Shi, Tingting, Himoto, Takashi, Tatsuta, Miwa, Moriya, Akio, Senoo, Tomonori, Tsutsui, Akemi, Nagano, Takuya, Takaguchi, Koichi, Ono, Masafumi, Masaki, Tsutomu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224826/
https://www.ncbi.nlm.nih.gov/pubmed/36583842
http://dx.doi.org/10.1007/s12072-022-10453-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224826/
https://www.ncbi.nlm.nih.gov/pubmed/36583842
http://dx.doi.org/10.1007/s12072-022-10453-1

Ejemplares similares